Twist Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.8 Mil. Twist Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $77.1 Mil. Twist Bioscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $590.0 Mil.
Twist Bioscience's debt to equity for the quarter that ended in Dec. 2023 was 0.16.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Twist Bioscience's Debt-to-Equity or its related term are showing as below:
TWST'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15 Med: 0.1 Max: 0.42
Current: 0.16
During the past 8 years, the highest Debt-to-Equity Ratio of Twist Bioscience was 0.42. The lowest was -0.15. And the median was 0.10.
Twist Bioscience Debt-to-Equity Historical Data
The historical data trend for Twist Bioscience's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Twist Bioscience Annual Data
|
|
Trend |
Sep16 |
Sep17 |
Sep18 |
Sep19 |
Sep20 |
Sep21 |
Sep22 |
Sep23 |
| Debt-to-Equity |
|
|
|
|
0.05 |
0.11 |
0.11 |
0.12 |
0.15 |
|
Twist Bioscience Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.13 |
0.13 |
0.14 |
0.15 |
0.16 |
Competitive Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Debt-to-Equity Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Debt-to-Equity falls into.
Twist Bioscience Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Twist Bioscience's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as
Twist Bioscience's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (Twist Bioscience) Business Description
Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Executives
| Robert F. Werner |
officer: Chief Accounting Officer |
2500 FABER PLACE, PALO ALTO CA 94303 |
| Dennis Cho |
officer: See Remarks |
C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Melissa A. Starovasnik |
director |
C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Jan Johannessen |
director |
5555 NE MOORE CT., HILLSBORO OR 97124 |
| William Banyai |
director, officer: Chief Operating Officer |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| Paula Green |
officer: VP of Human Resources |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| James M Thorburn |
officer: Chief Financial Officer |
C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126 |
| Nicolas Barthelemy |
director |
1750 BELLA LAGUNA CT, ENCINITAS CA 92024 |
| Robert Chess |
director |
|
| Patrick John Finn |
officer: VP of Sales and Marketing |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| Emily M. Leproust |
director, officer: President & CEO |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| Patrick Weiss |
officer: VP of Operations |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
| Keith Crandell |
director |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Kevin Bruce Yankton |
officer: Chief Accounting Officer |
1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104 |
| Mark Daniels |
officer: Chief Compliance Officer & GC |
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158 |
Twist Bioscience (Twist Bioscience) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TWST has been successfully added to your